logo

Protalix Biotherapeutics Inc. (PLX)



Trade PLX now with
  Date
  Headline
5/16/2022 6:52:20 AM Protalix BioTherapeutics Q1 Net Loss $2.3 Mln Or $0.05/Shr Vs Loss $5.5 Mln Or $0.14/Shr Last Year
4/4/2022 6:58:14 AM Protalix BioTherapeutics Announces Positive Topline Results From BALANCE Phase III Clinical Trial; Stock Up
3/31/2022 6:56:17 AM Protalix BioTherapeutics FY Net Loss $27.6 Mln Vs Net Loss $6.5 Mln Last Year
3/18/2022 6:55:51 AM Protalix, Chiesi Global Rare Diseases Announce BRIGHT Phase III Trial Of PRX-102 Fabry Disease Achieved Key Objectives
12/22/2021 6:59:53 AM Protalix :looks Forward With Anticipation To Continuing Progress In Advancing Potential Good Alternative For Fabry
12/22/2021 6:50:00 AM Protalix BioTherapeutics Issues 2021 Letter to Stockholders (Press Release)
11/15/2021 6:56:49 AM Protalix BioTherapeutics Q3 Net Loss $4.2 Mln, Or $0.09/shr Vs Net Loss Of $4.4 Mln Or $0.14/shr Prior Year
10/15/2021 8:41:32 AM Protalix, Chiesi Global Rare Diseases Announce Final Dosing Of Last Patient In Phase 3 BALANCE Trial Of PRX-102
10/11/2021 6:51:20 AM Protalix Biotherapeutics And Chiesi Global Rare Diseases Provide Regulatory Update On PRX-102 For Fabry Disease
8/26/2021 6:51:39 AM Protalix BioTherapeutics Announces Closing Of 7.50% Senior Secured Convertible Notes Due 2021 Exchange